Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2023-02-13 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
独立董事提名人声明
Board/Management Information Classification · 100% confidence The document is a public statement from the board of directors nominating an independent director candidate for the company's board. It details the nominee's qualifications, compliance with various regulatory requirements, and declarations regarding independence and eligibility. There is no financial data, no report of financial results, no voting results, no meeting materials, and no mention of dividends or capital changes. The content is focused on board/management information, specifically the nomination of a board member. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is about 4967 characters, which is consistent with a detailed announcement rather than a brief notice or a full report.
2023-02-13 Chinese
独立董事关于第三届董事会第十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the 11th meeting of the third board of directors of Sailong Pharmaceutical Group Co., Ltd. It includes opinions on the nomination of an independent director, appointment of a deputy general manager, guarantees for financing leasing business, and bank credit application with guarantees. The document is a formal board/management announcement related to governance and management decisions, not a financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial data. The content fits the category of Board/Management Information (MANG) as it announces changes and approvals related to board and senior management matters.
2023-02-13 Chinese
关于聘任公司副总经理的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a new deputy general manager at the company. It includes details about the board meeting, the nomination, and the biography of the appointed individual. There is no financial data, no mention of financial results, no regulatory certifications, or report publications. This fits the category of Board/Management Information, which covers announcements of changes in the company's board of directors or senior management.
2023-02-13 Chinese
关于公司补选独立董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election of a new independent director to the company's board due to the resignation of a previous independent director. It details the nomination, qualifications, and compliance with regulatory requirements for the new director. There is no financial data, earnings information, or report publication mentioned. The content clearly relates to changes in the company's board of directors, which fits the category of Board/Management Information (MANG). The document length is short and focused solely on this topic, confirming it is not a full report or other filing type.
2023-02-13 Chinese
关于公司向银行申请授信并由实际控制人提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company regarding its application for bank credit facilities and guarantees provided by its actual controllers. It details the credit amounts, guarantees, related party information, financial indicators, decision procedures, and board opinions. The document is a formal disclosure of financing activities and related guarantees, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive information about the financing and guarantees. The content fits best under 'Capital/Financing Update' as it updates on company fundraising and financing activities.
2023-02-13 Chinese
独立董事关于第三届董事会第十一次会议相关事项的事前认可意见
Board/Management Information Classification · 90% confidence The document is a statement of prior approval opinions from independent directors regarding matters to be discussed at the company's third board meeting. It involves approval of guarantees and credit applications related to financing activities. There is no financial data, no report publication, no voting results, no management changes, and no earnings or annual report content. The document is a governance-related approval statement by directors before a board meeting, which fits best under Board/Management Information (MANG) as it relates to board meeting matters and director opinions on company decisions.
2023-02-13 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.